Category - Developments

ObsEva (NASDAQ:OBSV) completed patient recruitment for its Phase 3 trial of nolasiban for the improvement of rates of pregnancy and live birth in patients undergoing assisted reproduction technology or in-vitro...

Genocea Biosciences (NASDAQ:GNCA) presented positive Phase 1/2a data regarding its neoantigen vaccine candidate, GEN-009, at the American Society of Clinical Oncology annual meeting. GEN-009 is a personalized cancer...

Proteostasis Therapeutics’ (NASDAQ: PTI) PTI-428 has been granted orphan drug designation by the European Medicines Agency (EMA) for the treatment of cystic fibrosis (CF). CF is caused by a mutation in cystic fibrosis...

Verona Pharma (NASDAQ:VRNA) initiated a Phase 2 trial of its metered-dose inhaler (MDI) formulation of ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Ensifentrine inhibits...

Titan Pharmaceuticals (NASDAQ:TTNP) signed a pharmacy services agreement with Southside Specialty Pharmacy, further expanding access to treatment with Probuphine (buprenorphine) implant, Titan’s unique maintenance...

Zenabis Global (TSX:ZENA) received an industrial hemp production license from Health Canada. “This is the second cultivation license we have received from Health Canada this year, and is another important step...

Epizyme (NASDAQ:EPZM) submitted an NDA to the FDA for tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma. Epithelioid sarcoma is a very rare soft tissue sarcoma. Tazemetostat is a small...

REGENXBIO (NASDAQ:RGNX) has completed dosing in its Phase 1/2a trial of RGX-314 for the treatment of wet age-related macular degeneration (AMD). RGX-314 uses REGENXBIO’s proprietary NAV gene delivery platform to...

Zenabis Global (TSX:ZENA) posted net revenue of $11.6-million from its cannabis and propogation segment for the first quarter of 2019, up from $3.4-million in the fourth quarter of 2018, which included only its cannabis...

BriaCell Therapeutics’ (TSXV:BCT; OTCQB:BCTXF) clinical findings were published at the 2019 American Society of Clinical Oncology (ASCO) annual meeting proceedings, a supplement to the Journal of Clinical Oncology...